This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



angiotensin II (Giapreza®)


Reference No. 3500

Publication date:
13/12/2019


Appraisal information

angiotensin II (Giapreza®) 2.5 mg/ml concentrate for solution for infusion


Company: La Jolla Pharmaceutical
BNF category: Cardiovascular system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 12/12/2019

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, angiotensin II (Giapreza®) cannot be endorsed for use within NHS Wales for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies
Statement of Advice (SOA)
Download